Interleukin-6 and tumor necrosis factor-α are associated with quality of life-related symptoms in pulmonary arterial hypertension - PubMed (original) (raw)

Randomized Controlled Trial

doi: 10.1513/AnnalsATS.201410-463OC.

Corey E Ventetuolo, Harold I Palevsky, David J Lederer, Evelyn M Horn, Stephen C Mathai, Diane Pinder, Christine Archer-Chicko, Emilia Bagiella, Kari E Roberts, Russell P Tracy, Paul M Hassoun, Reda E Girgis, Steven M Kawut

Affiliations

Randomized Controlled Trial

Lea Ann Matura et al. Ann Am Thorac Soc. 2015 Mar.

Abstract

Rationale: Inflammation is associated with symptoms in many chronic illnesses; however, this link has not been established in pulmonary arterial hypertension.

Objectives: The objective of this study was to investigate the association between inflammatory markers and quality of life-related symptoms in patients with pulmonary arterial hypertension. We hypothesized that higher circulating IL-6 and tumor necrosis factor-α levels would be associated with worse quality of life-related symptoms.

Methods: We performed a secondary analysis using baseline and 3-month assessments of 62 subjects in a clinical trial of aspirin and simvastatin to determine the association between plasma IL-6 and tumor necrosis factor-α levels and the Medical Outcomes Study Short Form-36 subscales (pain, vitality, mental health).

Measurements and main results: The mean age was 49.7±13.4 years; 87% were female. Higher IL-6 levels were significantly associated with lower Medical Outcomes Study Short Form-36 subscale scores, indicating worse bodily pain, vitality, and mental health (all P<0.01). Higher tumor necrosis factor-α levels were significantly associated with increased bodily pain, but better mental health scores.

Conclusions: IL-6 and tumor necrosis factor-α levels are associated with certain quality of life domains in patients with pulmonary arterial hypertension. Clinical trial registered with www.clinicaltrials.gov (NCT00384865).

Keywords: fatigue; interleukin-6; pain; pulmonary arterial hypertension; tumor necrosis factor-α.

PubMed Disclaimer

References

    1. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137:376–387. - PubMed
    1. Wu WH, Yang L, Peng FH, Yao J, Zou LL, Liu D, Jiang X, Li J, Gao I, Qu JM, et al. Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;187:303–310. - PMC - PubMed
    1. Galiè N, Hoeper MM, Humbert M, Torbicki A, Bachiery JL, Barbera JA, Beghhetti M, Corris P, Gaine S, Gibbs JS, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2009;30:2493–2537. - PubMed
    1. Matura L, McDonough A, Carroll D. Cluster analysis of symptoms in pulmonary arterial hypertension: a pilot study. Eur J Cardiovasc Nurs. 2012;11:51–61. - PubMed
    1. Matura LA, McDonough A, Carroll DL. Health-related quality of life and psychological states in patients with pulmonary arterial hypertension. J Cardiovasc Nurs. 2014;29:178–184. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources